Hamimed Mourad

Hamimed Mourad
French Institute of Health and Medical Research | Inserm · Cancer Research Center of Marseille (CRCM)

Doctor of Pharmacy (Pharm.D.) specialized in Toxicology (DEMS) & Pharmacokinetics (MSc)

About

12
Publications
3,434
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
2
Citations
Introduction
Mourad HAMIMED currently works at the SMARTc unit, Cancer Research Center of Marseille (CRCM). Mourad does research in Pharmacometrics.
Additional affiliations
November 2019 - present
Cancer Research Center of Marseille
Position
  • Pharmacometrician
November 2014 - August 2018
University Hospital Center of Constantine
Position
  • Medical Professional
June 2014 - July 2014
Military Regional Hospital of Constantine
Position
  • Practical internship at the Central Laboratory of the Military Regional University Hospital of Constantine.

Publications

Publications (12)
Article
Full-text available
Purpose Better understanding of pharmacokinetics of oral vinorelbine (VNR) in children would help predicting drug exposure and, beyond, clinical outcome. Here, we have characterized the population pharmacokinetics of oral VNR and studied the factors likely to explain the variability observed in VNR exposure among young patients. Design/methods We...
Poster
CPX-351 is a liposomal form encapsulating cytarabine and daunorubicin for treating Acute Myeloid Leukemia (AML) patients. Cytidine Deaminase (CDA) catabolizes free cytarabine in the liver, but to what extent it could affect as well the pharmacokinetics of liposomal cytarabine is yet to be investigated. Here we have studied the pharmacokinetics (PK)...
Poster
Implementing PK-guided dosing with monoclonal antibodies (mAbs) in oncology has been for long impaired by difficulties in developing appropriate (i.e., time- and cost-effective) bioanalytical methods suitable for routine Therapeutic Drug Monitoring, plus concerns regarding the exact PK/PD relationships of several biologics possibly blurred by the T...
Poster
Objectives:Defining a safe and effective dose in children is one of the biggest challenges in pediatric drug development. Pharmacometric tools are proposed as powerful quantitative techniques to leverage and integrate the collected data from pediatric clinical trials. Here we demonstrate and discuss the applications of nonlinear mixed effects (NLME...
Poster
Background: Resistance to PD1/L1 immune checkpoint inhibitors (ICIs) in advanced NSCLC patients is observed in about 80% of individuals with no robust predictive biomarker yet. The PIONeeR trial (NCT03493581) aims to predict such resistances through a comprehensive multiparametric biomarkers analysis. Methodology: Among the >300 advanced NSCLC pati...
Article
Aim: There is a crucial need for pharmacokinetic (PK) data of oral vinorelbine (VNR) in pediatric population. The aim of this work was to assess the PK profile of orally administered VNR in children with recurrent/progressive primary low-grade glioma (LGG). Methods: A multicentric, open-label, single-arm intervention phase II study was conducted...
Article
CPX-351 is a liposome encapsulating cytarabine and daunorubicin for treating Acute Myeloid Leukemia (AML) patients. To what extent differences in cytidine deaminase (CDA) activity, the enzyme that catabolizes free cytarabine in the liver, can affect the pharmacokinetics of liposomal cytarabine as well, is unknown. We have studied the pharmacokineti...
Poster
Full-text available
Les intoxications constituent un véritable problème de santé publique à l’échelle mondiale. Selon le rapport annuel 2017 des Statistiques sanitaires de l’OMS (1), chaque année, environ 109 695 personnes décèdent suite à une intoxication accidentelle. Parmi les causes des intoxications, en Algérie et d’après le Centre antipoison d’Alger (BILAN 2016)...
Poster
Full-text available
L’oxaliplatine (OXL) est un agent antitumoral de la classe des dérivés du platine, il a une activité significative contre le cancer colorectal avancé ou métastatique. La neuropathie périphérique induite par l’oxaliplatine ( NPIOXL) est fréquente ( approximativement 90 % des patients traités par Le OXL souffrent d’une neuropathie chimio-induite) et...
Poster
Full-text available
La présente étude passe en revue le profil de toxicité de l’hormonothérapie anticancéreuse (HT), notamment les effets aigus et tardifs associés à la déprivation hormonale androgénique et oestrogénique, et familiariser ainsi, tout professionnel de santé impliqué dans la prise en charge des patients cancéreux, avec les différents effets secondaires d...
Poster
Full-text available
L’objectif de ce travail est de mettre en évidence l’intérêt du dosage du méthotrexate, durant les cures de chimiothérapie, ainsi que de familiariser les cliniciens avec les différents aspects pratiques de ce dosage notamment les différentes modalités de prélèvement, conservation et interprétation des résultats. Dans un premier temps, nous présento...
Poster
Full-text available
Nous envisageons ici de passer en revue les interactions médicamenteuses chez les fumeurs et leurs implications potentielles pour les professionnelles de santé.

Network

Cited By